SciClone Pharmaceuticals Competitors and Similar CompaniesClear all
SciClone Pharmaceuticals's competitors and similar companies include Roivant Sciences and EyePoint Pharmaceuticals.
 SciClone Pharmaceuticals SciClone Pharmaceuticals (SciClone) is a global specialty pharmaceutical company with a product portfolio spanning major therapeutic markets including oncology, infectious diseases and cardiovascular disorders. |  EyePoint Pharmaceuticals EyePoint Pharmaceuticals (formerly pSivida) is a pharmaceutical company focused on the development of innovative miniaturized, sustained-release drug delivery products and technologies to treat serious, debilitating diseases of the eye that can lead to blindness. | ||
Founding Date | Founding Date 1989 | Founding Date 2014 | Founding Date 1987 |
Type | Type Private | Type Public | Type Public |
Tags | |||
Locations | Locations Foster City, US HQ | Locations London, GB HQ Basel, CH Boston, US New York, US | Locations Watertown, US HQ |
Employees | Employees 1102% decrease | Employees 908 | Employees 8453% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) 8.8 b | Valuation ($) 617.6 m |
Financial | |||
Revenue (est.) | Revenue (est.) $160.1m (FY, 2016) | Revenue (est.) $8.3m (FY, 2025) | Revenue (est.) $31.4m (FY, 2025) |
Net income | Net income $30.7m (FY, 2016) | Net income ($397.9m) (FY, 2025) | Net income ($232m) (FY, 2025) |
Funding | |||
Total funding raised | Total funding raised N/A | Total funding raised $ 1.9b | Total funding raised $ 40m |
For sources of this data, please see the company profile
View Company Profiles
Roivant Sciences
HQ
London, GB
Employees
908
Roivant Sciences is a company that develops and commercializes medicines.
View companyEyePoint Pharmaceuticals
HQ
Watertown, US
Employees
84
EyePoint Pharmaceuticals (formerly pSivida) is a pharmaceutical company focused on the development of innovative miniaturized, sustained-release drug delivery products and technologies to treat serious, debilitating diseases of the eye that can lead to blindness.
View company